N4 Pharma PLC Result of AGM (7885C)

TIDMN4P

RNS Number : 7885C

N4 Pharma PLC

19 June 2019

19 June 2019

N4 Pharma Plc

("N4 Pharma" or the "Company")

Result of AGM

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for vaccines and cancer treatments, announces that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. All resolutions were passed on a show of hands. The results of the proxy voting for the AGM is set out below.

 
                                                                        %                     % of 
                                                         Total         of                   issued 
                           Total votes   % of votes      Votes      votes   Total Votes      share          Votes 
     Resolution                 For(1)      cast(2)    Against    cast(2)       Cast(3)    capital    Withheld(4) 
     To receive 
      the annual 
      report and 
      audited 
      accounts 
      for the 
      year ended 
      31 December 
 1    2018                  16,362,457        99.99      1,134       0.01    16,363,591      16.13              0 
    --------------------  ------------  -----------  ---------  ---------  ------------  ---------  ------------- 
     To re-elect 
      Luke Cairns 
      as a director 
 2    of the Company        16,332,857        99.99      1,134       0.01    16,333,991      16.10         29,600 
    --------------------  ------------  -----------  ---------  ---------  ------------  ---------  ------------- 
     To elect 
      John Chiplin 
      as a Director 
 3    of the Company        16,332,857        99.99      1,134       0.01    16,333,991      16.10         29,600 
    --------------------  ------------  -----------  ---------  ---------  ------------  ---------  ------------- 
     To elect 
      Chris Britten 
      as a Director 
 4    of the Company        16,332,857        99.99      1,134       0.01    16,333,991      16.10         29,600 
    --------------------  ------------  -----------  ---------  ---------  ------------  ---------  ------------- 
     To re-appoint 
      Saffery 
      Champness 
      LLP as auditor 
      and authorise 
      directors 
      to determine 
 5    their remuneration    16,334,857        99.85     25,000       0.15    16,359,857      16.12          3,734 
    --------------------  ------------  -----------  ---------  ---------  ------------  ---------  ------------- 
     Authority 
      to allot 
 6    shares                16,331,657        99.82     30,200       0.18    16,361,857      16.12          1.734 
    --------------------  ------------  -----------  ---------  ---------  ------------  ---------  ------------- 
     Authority 
      to disapply 
      pre-emption 
 7    rights                16,330,457        99.97      5,334       0.03    16,335,791      16.10         27,800 
    --------------------  ------------  -----------  ---------  ---------  ------------  ---------  ------------- 
 

Notes:

1. Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution

   2.             Percentage of votes cast excludes Votes Withheld 
   3.             Total Votes Cast do not include withheld votes 

4. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution

Enquiries:

 
 N4 Pharma Plc               Via Scott PR 
  Nigel Theobald, CEO 
 Allenby Capital Limited    Tel: [phone] 
  James Reeve/Asha Chotai 
 Scott PR                    Tel: [phone] 
  Georgia Smith 
 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGBBGDLGUBBGCC

(END) Dow Jones Newswires

June 19, 2019 07:51 ET (11:51 GMT)